Mammary Cell News Volume 13.22 | Jun 10 2021

    By
    Justin.choi
    -
    0
    66







    2021-06-10 | MCN 13.22


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.22 – 10 June, 2021
    TOP STORY

    Structural Insight into BRCA1-BARD1 Complex Recruitment to Damaged Chromatin

    Investigators illustrated how BARD1 simultaneously recognized the DNA damage-induced mark H2AK15ub and DNA replication-associated mark H4K20me0 on the nucleosome.
    [Molecular Cell]

    AbstractGraphical Abstract

    Virtual Conference Exhibition: Organoids
    PUBLICATIONSRanked by the impact factor of the journal

    Impairment of a Distinct Cancer-Associated Fibroblast Population Limits Tumor Growth and Metastasis

    The authors showed that genetic deletion of the Endo180 (MRC2) receptor, predominantly expressed by a population of matrix-remodeling cancer-associated fibroblasts, profoundly limited tumor growth and metastasis; effects that could be recapitulated in 3D co-culture assays.
    [Nature Communications]

    Full Article

    Antibody-Drug Conjugates with Dual Payloads for Combating Breast Tumor Heterogeneity and Drug Resistance

    Scientists created homogeneous antibody-drug conjugates containing two distinct payloads that showed HER2-specific cell killing potency, desirable pharmacokinetic profiles, minimal inflammatory response, and marginal toxicity at therapeutic doses.
    [Nature Communications]

    Full Article

    Diet Alters Entero-Mammary Signaling to Regulate the Breast Microbiome and Tumorigenesis

    Researchers explored whether the microbiome of the gut and mammary gland mediates the dietary effects on breast cancer. In vitro models of the normal breast epithelium showed that lipopolysaccharide disrupted tight junctions and compromised epithelial permeability.
    [Cancer Research]

    AbstractPress Release

    Targeting the Tetraspanin CD81 Reduces Cancer Invasion and Metastasis

    Investigators showed that a unique anti-human CD81 antibody (5A6) effectively halted invasion of TNBC cell lines. They demonstrated that 5A6 induced CD81 clustering at the cell membrane and implicated JAM-A protein in the ability of this antibody to inhibit tumor cell invasion and migration.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    PELP1/Src-3-Dependent Regulation of Metabolic Pfkfb Kinases Drives Therapy Resistant Er+ Breast Cancer

    Researchers showed that cytoplasmic complexes composed of steroid receptor co-activators, PELP1 and SRC-3, modulated breast cancer stem cell expansion through upregulation of the HIF-activated metabolic target genes PFKFB3 and PFKFB4.
    [Oncogene]

    Abstract

    Combined Inhibition of DDR1 and CDK4/6 Induces Synergistic Effects in ER-Positive, HER2-Negative Breast Cancer with PIK3CA/AKT1 Mutations

    DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in breast cancer cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib.
    [Oncogene]

    Abstract

    Target Identification for Small-Molecule Discovery in the FOXO3a Tumor-Suppressor Pathway Using a Biodiverse Peptide Library

    Scientists used a library of peptides from diverse prokaryal genomes to screen macromolecular interactions promoting the nuclear relocalization of Forkhead Box O3 (FOXO3a) and assessed the impact of transcriptional changes on the growth of breast cancer cell lines.
    [Cell Chemical Biology]

    Full ArticleGraphical Abstract

    Metabolic Perturbations Sensitize Triple-Negative Breast Cancers to Apoptosis Induced by BH3 Mimetics

    The authors investigated the metabolic vulnerabilities of TNBC, particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics.
    [Science Signaling]

    Full Article

    Oxytocin Receptor Induces Mammary Tumorigenesis through Prolactin/P-STAT5 Pathway

    Oxytocin receptor overexpression led to an activation of prolactin/p-STAT5 pathway and created a microenvironment that promoted mammary-specific tumorigenesis.
    [Cell Death & Disease]

    Full Article

    Reduced Hyaluronan Cross-Linking Induces Breast Cancer Malignancy in a Caf-Dependent Manner

    Compared to normal mammary gland tissues, cross-linked hyaluronan levels were significantly decreased in breast cancer and associated with tumor malignancy.
    [Cell Death & Disease]

    Full Article

    Inhibition of Triple Negative Breast Cancer Metastasis and Invasiveness by Novel Drugs That Target Epithelial to Mesenchymal Transition

    Using an in vitro model of epithelial to mesenchymal transition (EMT), investigators showed that nitrofen interfered with the process of EMT and promoted mesenchymal to epithelial transformation.
    [Scientific Reports]

    Full Article

    Expression Pattern and Prognostic Impact of Glycoprotein Non-Metastatic B (GPNMB) in Triple-Negative Breast Cancer

    Among 759 specimens, immunohistochemistry exhibited glycoprotein non-metastatic B (GPNMB) expressions were variable in different subtypes and significantly higher in TNBC. GPNMB positively correlated with epithelial–mesenchymal transition regulators, mesenchymal marker vimentin, MMP and integrins.
    [Scientific Reports]

    Full Article

    Explore tools and resources for your return to the lab
    REVIEWS

    Long Noncoding RNAs in Triple-Negative Breast Cancer: A New Frontier in the Regulation of Tumorigenesis

    The authors highlight the association of several long noncoding RNAs in TNBC progression and treatment, along with their possible functions and mechanisms.
    [Journal of Cellular Physiology]

    Abstract

    Mammary Gland 3D Cell Culture Systems in Farm Animals

    Investigators discuss 3D cell culture systems as mammosphere organoids and their relevance for agronomic research.
    [Veterinary Research]

    Full Article

    INDUSTRY AND POLICY NEWS

    Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

    Byondis B.V. announced positive results from the Phase III TULIP® study. The trial compared the efficacy and safety of the company’s antibody-drug conjugate trastuzumab duocarmazine to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer.
    [Byondis B.V.]

    Press Release

    FEATURED EVENT

    Society for Developmental Biology 80th Annual Meeting

    Jul 12 – 16, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Director – Medical Affairs Oncology

    Gilead Sciences, Inc. – Foster City, California, United States

    Postdoctoral Scientist – Cancer Risk Loci

    Cedars-Sinai Medical Center – Los Angeles, California, United States

    Postdoctoral Fellow – Translational Cancer Research

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    Postdoctoral Fellow – Translational Breast Cancer Research

    University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Postdoctoral Fellowships – Clinical Cancer Prevention

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter